Physician profile
Rebeca Teplitz
NPI 1992330153
$14,756.97
in general payments reported to CMS, 2019-2025
28 companies · $1,850 in 2025
The $1,850 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2021: $702 · 2022: $1,872 · 2023: $7,905 · 2024: $2,319 · 2025: $1,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,692 · Consulting Fee: $4,536 · Travel and Lodging: $745 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,692.34 |
| Consulting Fee | $4,536.00 |
| Travel and Lodging | $745.03 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,907.37 | 2021-2024 | |
| Abbvie INC. | $1,696.18 | 2022-2025 | Skyrizi, Rinvoq |
| Dermavant Sciences, INC. | $656.64 | 2023-2024 | Vtama |
| Galderma Laboratories, L.P. | $648.11 | 2021-2025 | Twyneo, Aklief, Epsolay |
| Boehringer Ingelheim Pharmaceuticals, INC. | $589.38 | 2022-2024 | Spevigo, Cyltezo |
| Lilly USA, LLC | $573.70 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $562.31 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $514.71 | 2022-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $500.88 | 2021-2023 | Siliq |
| Incyte Corporation | $490.27 | 2022-2025 | Opzelura |
| E.R. Squibb & Sons, L.L.C. | $442.80 | 2021-2024 | Sotyktu |
| Janssen Biotech, INC. | $410.19 | 2023-2024 | Tremfya |
| Novartis Pharmaceuticals Corporation | $286.00 | 2023-2025 | |
| Pfizer INC. | $238.44 | 2024-2025 | |
| Amgen INC. | $215.36 | 2022-2025 | Otezla, Otezla |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $193.40 | 2021-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Sun Pharmaceutical Industries INC. | $174.58 | 2022-2025 | Ilumya |
| Genentech USA, INC. | $109.22 | 2019 | |
| Organon LLC | $108.25 | 2025 | |
| Janssen Scientific Affairs, LLC | $96.66 | 2022 | |
| Arcutis Biotherapeutics, INC. | $75.05 | 2025 | Zoryve |
| Botanix Sb INC | $73.94 | 2025 | Sofdra |
| Almirall LLC | $64.98 | 2021-2024 | Klisyri |
| Mayne Pharma Commercial LLC | $43.01 | 2025 | |
| Cipher Pharmaceuticals US LLC | $32.16 | 2025 | Natroba, Spinosad |
| Kyowa Kirin, INC. | $24.22 | 2022 | |
| Leo Pharma INC. | $14.95 | 2025 | Anzupgo |
| Merz North America, INC. | $14.21 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebeca Teplitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.